# OrigAMI-3 (NCT06750094)

> A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06750094
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Colorectal Neoplasms
- Interventions: Amivantamab; Cetuximab; Bevacizumab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Irinotecan
- Enrollment: 700
- Primary outcome: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 6
- X threads: 6
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=origami-3-nct06750094

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06750094", "email": "<work email>"}; the inbox owner confirms by the emailed link.